CHEST 2021


October 17th-20th

Biodesix presented two posters, a Learning Theater presentation and a case study at CHEST 2021. Details and links are below.

Posters & Presentations

Learning Theater: Clinical Utility of a Blood-based Biomarker Test Designed to Reduce Invasive Procedures on Benign Lung Nodules: Institutional Experience from Investigators Participating in the ORACLE Clinical Registry Study

Presenters: Jonathan Kurman, MD & Joshiah Gordon, DO MsC FCCP

Presented October 18th, 2021


CHEST Registrants: View Recording

Poster: Clinical Utility of the Nodify XL2® Blood-Based Risk Classifier for Management of Benign Pulmonary Nodules in a Real-World Observational Study

Authors: Michael Pritchett1, Barry Sigal2, Mark Bowling3, Melvin Morganroth4, Michael Bernstein5, Joseph Seaman6, Joshiah Gordon7, Archan Shah8, Jonathan Kurman9, Arthur Romero10, Mostafa Tabassomi11, Alejandro Aragaki12, Donald Berry13, Abishek Biswas14, Sandeep Bansal15, Trevor Pitcher16, Laura Peek16 & Steve Springmeyer16


Download Poster

Poster: A Blood-Based Autoantibody Test to Help Identify Likely Malignant Indeterminate Pulmonary Nodules: An opportunity for early diagnosis of lung cancer

Authors: Trevor Pitcher, Laura J Peek, Rachel Hartfield, Robbie Lunt, Steven C Springmeyer and James R Jett


Download Poster

Case Study: Nodule Dilemma: Proteomic Biomarker Discordance with PET Results

Authors: Jennifer Houpy, MD & Ajay Wagh, MD


View Case Study

Module heading text


One simple draw.
Two ways to help quickly and accurately decipher the risk of malignancy of a lung nodule.


Nodify Lung® testing consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.


Learn More

Biodesix Lung Color Logo

Biodesix Lung Reflex® testing consists of the GeneStrat® tumor profiling test and the VeriStrat® immune profiling test to provide physicians with timely molecular results to facilitate treatment decisions for patients with non-small cell lung cancer.


Learn More

We provide biopharmaceutical companies with end-to-end diagnostic services inclusive of diagnostic research and feasibility, assay development, clinical trial testing, and commercialization of companion diagnostics.


Learn More

Contact us with any questions